<DOC>
	<DOCNO>NCT00190801</DOCNO>
	<brief_summary>Pemetrexed show anti-tumor activity advance gastric cancer patient previous study , cisplatin widely use combination chemotherapy gastric cancer . Pemetrexed show synergy cisplatin preclinical model various human cancer . The introduction vitamin supplementation make treatment pemetrexed plus cisplatin safe well tolerate . The present phase 2 study effort determine efficacy safety combination pemetrexed cisplatin Korean patient gastric carcinoma prior palliative chemotherapy advance disease . The patient , give consent participate study , screen eligibility meet pre-defined study eligibility criterion , receive intravenous therapy combination pemetrexed cisplatin number time opinion treat physician appropriate . A response rate 30 % consider minimum activity level interest patient population .</brief_summary>
	<brief_title>Phase 2 Study Use Combination Pemetrexed Patients With Advanced Gastric Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>diagnosis adenocarcinoma stomach Stage IV disease amenable curative surgery . Disease status must measurable disease define RECIST criterion Performance Status 0 1 ECOG Scale adequate organ function . Signed informed consent patient Prior palliative chemotherapy advance disease . Known suspected brain metastasis Second primary malignancy clinically detectable time consideration study enrollment . Concurrent administration tumor therapy Inability interrupt aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) 2 day , day , 2 day dose ALIMTA plus cisplatin . Inability unwillingness take folic acid , vitamin B12 supplementation , dexamethasone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>